Clinical Trial Update: Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis [Phase 3]

View source ↗

Summary

This clinical trial update describes a Phase 3 study comparing Nipocalimab and Efgartigimod for generalized myasthenia gravis, sponsored by Janssen Research & D…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• Efgartigimod (efgartigimod)
• Nipocalimab (nipocalimab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Myasthenia Gravis | Phase 3 | Status: RECRUITING